Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYSERT vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Treatment of vulvovaginal candidiasis in adult and adolescent females (FDA-approved),Off-label: Treatment of mixed vaginal infections (bacterial vaginosis with candidiasis),Off-label: Prevention of recurrent vulvovaginal candidiasis
Mild to moderate pain,Fever
10 mg orally once daily at bedtime, with or without food.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Nystatin is not absorbed systemically; metabolized in the gut via unknown pathways, excreted unchanged in feces. Sertaconazole: Primarily hepatic metabolism via CYP3A4 to inactive metabolites; minimal systemic absorption (<1%).
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Vd approximately 7-10 L/kg, indicating extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability is ~60% due to first-pass metabolism; not available parenterally.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). Severe renal impairment (e GFR <30 m L/min) not studied; use with caution. No pharmacokinetic data for dialysis.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: not recommended due to lack of data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for pediatric patients (safety and efficacy not established).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment recommended; monitor for adverse effects due to age-related decreased clearance. Starting dose of 5 mg may be considered for elderly patients with frailty or comorbidities.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Hypersensitivity reactions (urticaria, angioedema) possible; discontinue if irritation occurs; avoid intravaginal use in patients with known hypersensitivity to any azole or polyene antifungals; not for oral, ophthalmic, or systemic use; may weaken latex condoms and diaphragms (avoid use within 72 hours of product use); pregnancy category C (use only if clearly needed); breastfeeding women: use caution due to possible infant exposure.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Known hypersensitivity to nystatin, sertaconazole, or any component of the formulation; acute hepatic porphyria (sertaconazole component); concurrent use with terfenadine, astemizole, cisapride, or other CYP3A4 substrates with narrow therapeutic index (sertaconazole component).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No known food interactions with topical nystatin. For oral suspension, avoid food or drink for 30 minutes after administration to maximize contact time.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal abnormalities at high doses. Second and third trimesters: Risk of preterm labor, low birth weight, and neonatal adaptation syndrome (e.g., respiratory depression, jitteriness) with chronic use. Avoid use unless benefit outweighs risk.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted in breast milk; M/P ratio not established. Use with caution in breastfeeding, especially in neonates or preterm infants, due to potential sedation or respiratory depression. Monitor infant for drowsiness, poor feeding, and weight gain.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No standard dose adjustments; use lowest effective dose for shortest duration. Pharmacokinetics in pregnancy: increased clearance may require higher doses for analgesia; however, avoid long-term use due to fetal risks. For labor analgesia, typical doses apply with careful monitoring.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
NYSERT (nystatin) is a polyene antifungal used topically for Candida infections. Do not use for systemic fungal infections. Monitor for local irritation or sensitization. In oral thrush, ensure contact time by holding suspension in mouth before swallowing. For vaginal use, continue through menstruation. For diaper rash, combine with barrier cream and frequent diaper changes.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Use exactly as directed for the full duration, even if symptoms improve.,For oral suspension: swish in mouth for several minutes before swallowing; do not eat or drink for 30 minutes after.,For topical cream: apply thin layer to affected area; avoid contact with eyes.,For vaginal tablets: insert high into vagina at bedtime; use sanitary pad to protect clothing.,Stop use and consult doctor if rash, irritation, or allergic reaction occurs.,Keep out of reach of children; do not use if allergic to nystatin or any ingredient.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYSERT vs ACEPHEN, answered by our medical review team.
NYSERT is a Antifungal that works by NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYSERT and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYSERT is: 10 mg orally once daily at bedtime, with or without food.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYSERT and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYSERT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal abnormalities at high doses. Second and third trimesters: Risk of preterm labor, low. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.